Received Apr 10, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
flu like symptoms; Fatigue; low energy; sensitive digestive system; This non-serious case was reported by a consumer via call center representative and described the occurrence of influenza-like symptoms in a elderly female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix with an associated reaction of injection site pain (received 1st dose 4 months ago, refer case US2026042682). Concurrent medical conditions included rheumatoid arthritis. In FEB-2026, the patient received the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced influenza-like symptoms (Verbatim: flu like symptoms), fatigue (Verbatim: Fatigue), energy decreased (Verbatim: low energy) and gastrointestinal disorder (Verbatim: sensitive digestive system). The outcome of the influenza-like symptoms, fatigue, energy decreased and gastrointestinal disorder were resolving. It was unknown if the reporter considered the influenza-like symptoms, fatigue, energy decreased and gastrointestinal disorder to be related to Shingrix. It was unknown if the company considered the influenza-like symptoms, fatigue, energy decreased and gastrointestinal disorder to be related to Shingrix. Linked case(s) involving the same patient: US2026042682 Additional Information: GSK receipt date 31-MAR-2026 After 2nd dose of shingrix dose the patient felt flu like symptoms for 1 week, then the flu like symptoms recur for several weeks, fatigue, low energy, sensitive digestive system. The second Shingrix dose was administered slow as a request by the patient as the first shot was injected quickly. The patient mentioned feeling better the last couple days. The reporter consented to follow up. The batch number was not provided upon follow- up with the reporter.; Sender's Comments: US-GSK-US2026042682:
Rheumatoid arthritis